Gottfried von Keudell, MD, PhD
Hodgkin and Non-Hodgkin Lymphomas; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B-cell Lymphoma; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. von Keudell accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, PhD, University of Hamburg, Germany
Internal Medicine - University of Chicago
Hematology/Oncology - University of Chicago
Internal Medicine; Hematology; Oncology
During my training, I was fascinated by cancer biology and was inspired by the pursuit of new approaches that hold promise for improved outcomes and a better quality of life for people with blood cancers. I am currently the principal investigator of several clinical trials evaluating new lymphoma treatments, either as single agents or in combination with immunotherapy.
Patients often ask me if their disease is treatable. For most people, the answer is yes, thanks to the explosion of promising new targeted treatments, immunotherapies, and supportive care options that we have seen in recent years. I am fortunate to be part of a team that has led to some of these breakthroughs.
I believe that every person in my care deserves my full attention and dedication so that they feel supported and cared for during a difficult time in their lives. My goal is to convey a sense of hope and confidence to ease the anxiety that comes with a diagnosis of lymphoma.
Outside of work I enjoy playing the piano, being outdoors with my dog, and attending cultural events.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Investigated by Dr. von Keudell
- A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
- A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
- A Phase II Study of Entinostat plus Pembrolizumab Immunotherapy for Recurrent or Persistent Hodgkin Lymphoma
- A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
- Clinical Trials Co-Investigated by Dr. von Keudell
- A Phase I Study of IGM-2323 in People with Relapsed or Persistent Non-Hodgkin Lymphoma
- A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
- A Phase IB/III Study of Lenalidomide and Rituximab plus Tazemetostat or Placebo in Patients with Recurrent or Persistent Follicular Lymphoma
- A Phase II Study of Brentuximab Vedotin with Chemotherapy and Immunotherapy in People with Classical Hodgkin Lymphoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Follicular lymphoma. Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J. Nat Rev Dis Primers. 2019 Dec 12;5(1):83. doi: 10.1038/s41572-019-0132-x. Review.
The Role of PI3K Inhibition in Lymphoid Malignancies. von Keudell G, Moskowitz AJ. Curr Hematol Malig Rep. 2019 Jul 29. doi: 10.1007/s11899-019-00540-w. [Epub ahead of print] Review.
Will GALEN become more RELEVANT? von Keudell G, Younes A. Lancet Haematol. 2019 Aug;6(8):e391-e392. doi: 10.1016/S2352-3026(19)30136-X. Epub 2019 Jul 8. No abstract available.
Novel therapeutic agents for relapsed classical Hodgkin lymphoma. von Keudell G, Younes A. Br J Haematol. 2019 Jan;184(1):105-112. doi: 10.1111/bjh.15695. Epub 2018 Dec 11. Review.
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS. J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. J Clin Oncol. 2018 Oct 4:JCO1800122. doi: 10.1200/JCO.18.00122. [Epub ahead of print]
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cancer. 2017 Oct 1;123(19):3763-3771. doi: 10.1002/cncr.30818. Epub 2017 Jun 22.
Visit PubMed for a full listing of Dr. von Keudell’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gottfried von Keudell discloses the following relationships and financial interests:
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.